Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan

Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.o.c

Atomic Energy Council-Institute of Nuclear Energy Research

Institute of Nuclear Energy Research

Institute of Nuclear Energy Research, Atomic Energy Council

Atomic Energy Council

Tsinghua University

Johns Hopkins University

National Yang Ming Chiao Tung University

Wuu-Jyh Lin

Jenn-Tzong Chen

Mei-Hui Wang

Hung-Man Yu

Ting-Shien Duh

Kun-Liang Lin

Ming-Hsin Li

Li-Yuan Huang

Shiou-Shiow Farn

Chuan-Yi Chien

Mao-Hsung Chang

Lie-Hang Shen

Yuan-Chuan Lee

Hsin-Ell Wang

Jen-Tsung Wang

Sun-Rong Huang

Ying-Ming Tsai

Wen-Chin Su

Chien-Hsin Lu

Reiko Takasaka Lee

Hao-Wen Kao

Cheng-Fang Hsu

Wen-Song Hwang

Chia-Chieh Chen

Tsai-Yueh Luo

Chyng-Yann Shiue

Kuan-Yin Chen

Ming-Chao Kuo

Ying-Kai Fu

Mao-Chi Weng

Chien-Chung Hsia

Bin Lin

Ho-Lien Huang

Chung-Shan Yu

Ping-Yen Wang

Yean-Hung Tu

Der-Chi Tien

Yan-Feng Jiang

Rui-Yu Chen

Yu Lung Chang

Show-Wen Liu

Shu-Hung Lin

Chih-Yuan Lin

Shui-Cheng Lee

Haw-Jan Chen

Tain-Shi Zen

Jyun-Hong Chen

Ching-Jun Liou

Chao-Cheng Chen

Kwan-Hwa Chi

Yean-Chang Chen

Hsueh-Hsuan Liu

Dow-Che Chen

Ching-Shiuann Yang

Meng-Chou Lee

Kuo-Yuan Chu

Chun-Hao Tseng

Chien-Jen Chen

Tseng-Chung Huang

Chun-Yi Wu

Hsin-EII Wang

Song-Un Tang

Cheng-Hung Chien

Ai-Ren Lo

Jun-Chieh Tsai

Wun-Shen Lan

Kang-Wei Chang

Ping-Yen Huang

Ying-Chieh Wang

Sheng-Po Huang

Wei-Ming Li

Te-Sheng Liang

Ying-Hsia Shih

Yen-Hung Tu

Wei-Ti Kuo

Hung-Wen Yu

Chun-Nan Yeh

Ying-Cheng Huang

Kun-Ju Lin

Shu-Fan Tien

Chuan-Lin Chen

Wen-Yi Chang

Jia-Rong Chen

Sun-Rong Hwang

Jainn-Hsin Lu

Wei-Yuan Lee

Ming-Hsin Lee

Te-Hsing Wu

Ying-Kai c/o Atomic Energy Council Fu

Wei-His Chen

Dow-Chi Chen

Ting-Shien c/o Atomic Energy Council Duh

Bor-Tsung Hsieh

Ying-Ming c/o Atomic En Council-Inst Of Nucl Energy Tsai

A method is provided to purify [F-18]FEONM under a high pressure. The synthesis processes of [F-18]FEONM are integrated. An isolation process of non-toxic radio-high performance liquid chromatography (radio-HPLC) is used to purify the crude product. The method integrates a convention [F-18]FDG synthesizer and a novel radio-HPLC system together in a heat chamber. After radiofluorinating the precursor, the reaction product is purified with an alumina solid-phase column in advance to obtain the crude product while fluorine-18 is removed. Then, diphenyl semipreparative HPLC column is used for a final purification. A non-toxic solvent is used for mobile-phase eluting to remove the unreacted precursor and the phase-transfer solvent. The radiofluorination has a reaction yield about 50 percent (%). The method has an uncorrected radiochemical yield of 10&#x2dc;20%. Both of the radio-HPLC and the radio-thin layer chromatography (radio-TLC) have radiochemical purity higher than 95%.

Method of high-pressure purification of [f-18]FEONM

The present invention provides a hexa-lactoside-triazanonane triacetic acid (NOTA) derivative, a method for radiolabeling a hexa-lactoside positron emission tomography (PET) imaging agent for a liver receptor with Ga-68, and a hexa-lactoside PET imaging agent for a liver receptor. The hexa-lactoside-NOTA derivative is a conjugate of six chains of lactose with NOTA obtained by conjugating hexa-lactoside to a chelating agent p-thiocyanate-benzyl-triazanonane diacetic acid-glutamic acid in the presence of triethyl amine/dimethyl formamide as a solvent. The radiolabeling method comprises labeling with Ga-68 at room temperature. According to the present invention, the labeling effect is stable, the labeling efficiency of the labeled product is greater than 95%, the labeled product is highly stable and the radiochemical purity is still greater than 90% after 4 hours.

Hexa-lactoside-triazanonane triacetic acid (NOTA) derivative, method for radiolabeling hexa-lactoside positron emission tomography (PET) imaging agent for liver receptor with Ga-68, and hexa-lactoside PET imaging agent for liver receptor

Disclosed herein are a multivalent saccharide complex, a radioactive multivalent saccharide complex contrast agent and use thereof. The multivalent saccharide complex has a chelator, a linker, and glucose, and is configured to diagnose and evaluate the therapeutic effect of cancers.

Multivalent saccharide complex, radioactive multivalent saccharide complex contrast agent, and use thereof

The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof. The above-mentioned pharmaceutical composition is applied to evaluate a tumor accumulation time, so as to establish the optimal policy for a radiofrequency- or laser-induced thermal adjuvant therapy for tumors.

Radiolabeled active targeting pharmaceutical composition and the use thereof

The present invention provides a method for preparing a 6-aminohexyl lactoside-NOTA conjugate. The preparation method comprises brominating perbenzoylated lactose with hydrobromic acid; glycosylating 6-azidohexanol to obtain 6-azidohexyl perbenzoyl lactoside; and deprotecting this precursor in two steps to obtain 6-aminohexyl lactoside and conjugating 6-aminohexyl lactoside to NCS-benzyl-NODA GA (i.e. 2,2'-(7-(1-carboxy-4-((4-isothiocyanate benzyl) amino)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl) diacetic acid) in triethyl amine as an alkaline solvent, to obtain a 6-aminohexyl lactoside-NCS-benzyl-NODA GA conjugate. In this novel preparation method, no deglycosylated side product is produced, such that the yield is considerably increased to 46%. Therefore, the method is suitable for future massive production since the requirement for repeated preparations for massive production is reduced, and the impurities produced in the previously scaled-up preparation process are not present.

Method for preparing 6-aminohexyl lactoside-NOTA conjugate

A [F-18]FEONM precursor is synthesized. 2-bromoethanol is added to further connect an atom of oxygen at an N terminal of the precursor. Four atoms of carbon can be further connected. Thus, better fat-solubility is obtained along with the increase in carbon. Positioning in brain imaging becomes better.

Method of fabricating [F-18]FEONM precursor

Disclosed herein is a bispecific peptide conjugate comprising an epidermal growth factor receptor (EGFR) targeting peptide, an &#x3b1;v&#x3b2;3 integrin targeting peptide, and a linker, where the linker is conjugated respectively to the EGFR targeting peptide and the &#x3b1;v&#x3b2;3 integrin targeting peptide.

Bispecific peptide conjugate and radioactive bispecific peptide imaging agent

The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.

Preparation method of radiation sensitive copolymer carrier for coating radiated nanoparticles and chemotherapy drugs

A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.

Quantification method for remaining liver function and novel liver receptor imaging agent

A novel gall bladder image agent which includes a radio-labelled MAG3-tri-galactosamine, and its preparation method, which includes reacting mercaptoacetyltriglycine (MAG3)-tri-galactosamine, SnF2 and Tc-99m in the presence of a phosphate buffer solution (at pH of from 10.0&#x2dc;12.0) to obtain Tc-99m-MAG3-tri-galactosamine, when the MAG3-tri-galactosamine is MAG3-DCM-Lys(Gah-GalNAc)3 (where DCM represents a dicarboxymethyl group, and Gah represents a glycine-aminohexyl group), it obtains a labelling yield of at least 90%, and its specific radioactivity is at least 7.0&#xd7;109 Bq/mg.

Gall bladder imaging agent and its preparation method

The present invention relates to an automatic system for synthesizing iodine-123 meta-iodobenzylguanidine (I-MIBG), which comprises a first reactor for subjecting radioactive iodine-containing sodium iodide and meta-iodobenzylguanidine (MIBG) sulfate to an iodine-iodine exchange reaction to obtain radioactive iodine labeled MIBG; a purification unit for purifying the iodine labeled MIBG; and a second reactor for substituting a solvent used in purification with a phosphate buffer to obtain a phosphate solution containingI-MIBG. The present invention also relates to an automatic device for dispensingI-MIBG, which comprises the automatic system for synthesizingI-MIBG, a radioactivity measuring unit, and a dispensing and packing unit.

[object Object]

A radiocontrast agent for tau protein is provided. The agent is selectively and strongly bound to tau protein and its tangle found in brain diseases like Alzheimer's disease (AD). The agent is especially suitable to be used in PET imaging for brain diseases. Or, the agent can be used to inhibit tau protein overexpressive and, thus, stop the proceeding of brain disease.

Compound of radiocontrast agent for tau protein

The present invention establishes a fast and simple [F-18] FLT synthesis process. Solid extraction units are used for purification to achieve an equally high and constant radiochemical yield and purity in a short period of time. By using a separation method, the impurities are reduced successfully while the total synthesis time is shortened. The radiochemical purity and the corrected radiochemical yield are both high.

Method for F-18 FLT synthesis

A method for preparing a precursor used to label hepatocyte receptors is revealed. The precursor contains a bifunctional structure including trisaccharide and DTPA ligand. During synthesis processes of the precursor, silica gel columns and Reverse phase-18 (RP-18) columns are used for purification. Thus both the purification times and cost of each purification are reduced. Moreover, use diethyl ether to facilitate precipitation of products and remove a part of coupling reagent. Removing the coupling reagent helps purification of products. Furthermore, N,N-bis(carboxymethyl)-L-lysine hydrate and benzyl chloroformate are coupled to form a trisaccharide skeleton so as to ensure the yield rate of trisaccharide structure.

Method for preparing precursor used for labeling hepatocyte receptor and containing trisaccharide and DTPA ligand

Growing community of inventors

Taoyuan County, Taiwan

Wuu-Jyh Lin